These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
4. Long-term low-dose calcitriol treatment in predialysis chronic renal failure: can it prevent hyperparathyroid bone disease? Nordal KP; Dahl E; Halse J; Attramadal A; Flatmark A Nephrol Dial Transplant; 1995; 10(2):203-6. PubMed ID: 7753453 [TBL] [Abstract][Full Text] [Related]
5. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination. Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862 [TBL] [Abstract][Full Text] [Related]
7. Prevention of metabolic bone disease in the pre-end-stage renal disease setting. Coburn JW; Elangovan L J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772 [TBL] [Abstract][Full Text] [Related]
8. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients. Lee SH; Huang TS; Hsieh SJ Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625 [TBL] [Abstract][Full Text] [Related]
9. Effects of long-term therapy with calcitriol in patients with moderate renal failure. Healy MD; Malluche HH; Goldstein DA; Singer FR; Massry SG Arch Intern Med; 1980 Aug; 140(8):1030-3. PubMed ID: 6893118 [TBL] [Abstract][Full Text] [Related]
10. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results. Coen G; Mazzaferro S; Bonucci E; Ballanti P; Massimetti C; Donato G; Landi A; Smacchi A; Della Rocca C; Cinotti GA Miner Electrolyte Metab; 1986; 12(5-6):375-82. PubMed ID: 3492662 [TBL] [Abstract][Full Text] [Related]
11. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Goldenberg MM Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413 [TBL] [Abstract][Full Text] [Related]
12. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure. Panichi V; Andreini B; De Pietro S; Migliori M; Taccola D; Giovannini L; Ferdeghini M; Palla R Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556 [TBL] [Abstract][Full Text] [Related]
13. Calcitropic hormonal status in north Indian patients with end-stage renal disease. Singh AK; Avula S; Kher V; Rao DS; Mithal A Natl Med J India; 1999; 12(5):202-7. PubMed ID: 10612998 [TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone changes during phosphorus load in patients with chronic renal insufficiency with low serum parathyroid hormone or adynamic bone disease. Cuppari L; Carvalho AB; Lobão RR; Martini LA; Cendoroglo M; Ventura RT; Draibe SA Clin Nephrol; 2001 Jul; 56(1):35-43. PubMed ID: 11499657 [TBL] [Abstract][Full Text] [Related]
15. 1,25(OH)2D3 and renal function. A controlled clinical study in normal elderly women. Jensen GF; Christiansen C; Transbøl I Acta Med Scand; 1982; 211(1-2):51-4. PubMed ID: 7041522 [TBL] [Abstract][Full Text] [Related]
16. The interaction of PTH and dietary phosphorus and calcium on serum calcitriol levels in the rat with experimental renal failure. Martin-Malo A; Rodriguez M; Martinez ME; Torres A; Felsenfeld AJ Nephrol Dial Transplant; 1996 Aug; 11(8):1553-8. PubMed ID: 8856210 [TBL] [Abstract][Full Text] [Related]
17. Dihydrotachysterol and calcitriol in long-term dialyzed patients with renal bone disease. Wilczek H; Stĕpán J; Pacovský V Acta Univ Carol Med (Praha); 1986; 32(5-6):339-43. PubMed ID: 3439519 [No Abstract] [Full Text] [Related]
18. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Dressler R; Laut J; Lynn RI; Ginsberg N Clin Nephrol; 1995 May; 43(5):324-31. PubMed ID: 7634548 [TBL] [Abstract][Full Text] [Related]
19. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment. Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788 [TBL] [Abstract][Full Text] [Related]